C. Gause

发表

Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer

L. Pusztai, R. Berger, V. Karantza, 2015 .

A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer.

M. Dolled-Filhart, K. Emancipator, T. Seiwert, 2014 .

Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.

J. Malvehy, R. Dummer, J. Kirkwood, 2016 .

Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.

Tae Won Kim, L. Diaz, E. Van Cutsem, 2017 .

Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine

R. Railkar, K. Friese, L. Woelber, 2009, Archives of Gynecology and Obstetrics.

A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

D. Siegel, J. Miguel, M. Dolled-Filhart, 2014 .

A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies.

M. Dolled-Filhart, K. Emancipator, P. Zinzani, 2014 .

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.

H. Goldschmidt, M. Dimopoulos, S. Jagannath, 2016, Clinical lymphoma, myeloma & leukemia.

LBA23A PHASE 1B STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) IN PATIENTS (PTS) WITH ADVANCED UROTHELIAL TRACT CANCER

E. Plimack, R. Berger, M. Dolled-Filhart, 2014 .

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

M. Dimopoulos, D. Siegel, P. Richardson, 2014, Blood Cancer Journal.

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

M. Dimopoulos, D. Siegel, P. Richardson, 2014, Blood Cancer Journal.

14P * KEYNOTE-012: A phase Ib study of pembrolizumab (MK-3475) in patients (pts) with metastatic triple-negative breast cancer (mTNBC)

L. Pusztai, R. Berger, V. Karantza, 2015 .

Abstract PD5-1: Results from the phase 2 trial of ridaforolimus, dalotuzumab, and exemestane compared to ridaforolimus and exemestane in advanced breast cancer

J. Baselga, A. Musolino, H. Rugo, 2015 .

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

J. Lunceford, T. Mcclanahan, R. Berger, 2016, The Lancet. Oncology.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer.

T. Choueiri, E. Plimack, G. Sonpavde, 2015 .

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

F. X. Bosch, N. Muñoz, M. Lehtinen, 2007 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: Results of a phase IB study.

E. Plimack, R. Berger, M. Dolled-Filhart, 2015 .

Melanoma and immunotherapy bridge 2015

Andrew J. Park, Ludmila V. Danilova, David C. Smith, 2016, Journal of Translational Medicine.

KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer.

J. Machiels, K. Harrington, R. Swaby, 2015 .

Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women.

R. Railkar, O. Bautista, E. Barr, 2008, American journal of obstetrics and gynecology.

A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population

M. Dimopoulos, D. Siegel, P. Richardson, 2010 .

A case-control study of lung cancer mortality in six Gila Basin, Arizona smelter towns.

R. Stone, D. Prybylski, G. Marsh, 1997, Environmental research.

A case-control study of lung cancer mortality in four rural Arizona smelter towns.

R. Stone, D. Prybylski, G. Marsh, 1998, Archives of environmental health.

24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma

J. Malvehy, R. Dummer, J. Kirkwood, 2015 .

The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development.

K. Anderson, E. Rubin, C. Gause, 2011, Cancer discovery.

A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma.

R. Dummer, J. Kirkwood, A. Ribas, 2015 .

Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.

T. Choueiri, M. Atkins, A. Ribas, 2015 .

LBA31A PHASE IB STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) IN PATIENTS (PTS) WITH HUMAN PAPIILLOMA VIRUS (HPV)-POSITIVE AND NEGATIVE HEAD AND NECK CANCER (HNC)

J. Lunceford, R. Berger, M. Dolled-Filhart, 2014 .

A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

J. Baselga, H. Rugo, A. Tan, 2017, Breast Cancer Research and Treatment.

MP68-11 A PHASE 1B STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED UROTHELIAL CANCER

E. Plimack, M. Dolled-Filhart, J. Bellmunt, 2015 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

A Risk Assessment for Occupational Acrylonitrile Exposure Using Epidemiology Data

R. Stone, T. Starr, A. Youk, 2004, Risk analysis : an official publication of the Society for Risk Analysis.

A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

J. Baselga, A. Musolino, H. Rugo, 2017, Breast Cancer Research and Treatment.

Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients

M. Pietanza, D. Bajorin, J. Brahmer, 2024, European journal of cancer.